Finland's product-liability rewrite and Novo's China deal
2026-09-29 · The rulebook · Finland's product-liability rewrite, Novo Nordisk's Hengrui obesity deal, Prehn's Fed-is-trapped case, tested
How it is made. Aavistus Daily is written and voiced by our own systems, every morning, from data we gather ourselves. The voices are synthetic. Every fact is traced to a source on this page, and every dated call is settled in public on the calibration page. The presenters, Nora and Callum, are named characters, not people.
Aavistus is a new framework, still under development. We will make mistakes, and every dated call is settled here in public so you can see them; the aim is to keep calibrating until the record beats the average forecaster, not to sound right.
Finland's product-liability bill for digital goods lands at parliament, Novo Nordisk pays $2.6bn for a Chinese oral obesity molecule, and Felix Prehn's Fed-is-trapped case gets a check.
Finland's product-liability bill for digital goods
Government bill HE 190 of 2026 landed at the Eduskunta on the 24th of September. It amends the Product Liability Act and chapter 12 of the Consumer Protection Act. Where we sit in the lifecycle: proposal, not vote. Committee assignment comes first, almost certainly to the Economic Affairs Committee, then a reading, then a plenary vote. On the current parliamentary calendar the final vote falls in the winter session.
The substance matters because it is a substantial rewrite of European product-liability first principles. The old regime, written for physical goods, sits awkwardly on software. The direction of the European regulatory update on this file is to bring software, artificial intelligence systems and digital services within the scope of strict product liability. Alongside it, plaintiff-side rules soften: disclosure obligations on producers become stronger and, in specified cases, the burden of proof around defect and causation shifts — the plaintiff can rely on a rebuttable presumption once conditions are met.
Concretely, two things change for a Nordic software exporter. First, the courtroom probability of a defect finding goes up because plaintiffs no longer have to prove the counterfactual entirely from cold. Second, digital services that update over time are inside the frame — an over-the-air update that introduces a defect is a producer act. For Nordic industrials with software layers, and for the mid-cap Finnish software exporters selling into consumer channels, the compliance overhead moves.
The read: this is a cost item that shows up as small margin compression in 2027 and 2028 rather than a headline-moving event. Insurance markets have been repricing product liability; large Nordic listed companies have this in their reserving already. The trigger to reprice is a scope amendment in committee that either narrows the software definition or widens the plaintiff's presumption. What would make the priced-in view wrong is any large Nordic listed company adding a material qualifier to product-liability reserves in the fourth-quarter reporting window.
Novo Nordisk buys breadth in China
Novo Nordisk signed a two-point-six-billion-dollar licensing deal with China's Hengrui Pharma this morning for a once-weekly oral weight-loss pill in the same drug family as Ozempic. This is Novo buying breadth in the obesity pipeline rather than building it.
Read carefully, the deal says three things. One, the internal pipeline is not enough to defend market share against Eli Lilly on the oral obesity opportunity. Two, management is willing to spend to catch up — a positive on management awareness, not on internal productivity. Three, the licensing route implies Novo does not have a comparable oral asset moving through its own late-stage machinery on the same timeline. If it did, this deal would not have been priced at these terms.
A drawdown tells you nothing about whether the pipeline story is done being repriced. The right question is what event resets consensus. For Novo Nordisk that is either a Phase 3 readout on an internal oral candidate that beats Lilly's most recent comparable, or a Phase 3 readout on the Hengrui molecule that puts a specific product on a specific calendar. Absent that, the case for adding Novo Nordisk at these levels is not there. What would make the pipeline-slippage view wrong is a Phase 3 readout before year-end showing an internal oral candidate above Lilly on weight loss at twelve weeks and on gastrointestinal tolerability.
Prehn's Fed-is-trapped case, tested
Felix Nikolas Prehn, on his own channel this weekend, argued that the Federal Reserve is trapped.
The trapped framing is only correct if you concede the Fed still has room to hike without triggering recession. The labour numbers say it does.
On the PCE recalibration: yes, methodology matters, and an official rate that reads half a point lower would give the FOMC cover to pause. But the Bureau's methodology reviews are pre-announced and documented in a public schedule. Calling it a quiet reset is theatre. On the Treasury General Account: it is the fiscal calendar, not stimulus. On the supply-side cost channel: it is a real mechanism, second-order to the demand channel that is doing the work of the current cycle. Prehn's argument gives you a reason for the terminal rate to be lower than a pure demand model predicts. It does not give you a reason for the Fed to be trapped.
None of this moves the range view on the ten-year. The base case — the yield holds a range through year-end with a modest S&P de-rating rather than a full break — holds. What would make it wrong is a sustained upward break on the ten-year with no equity break. Supporting the not-breaking side: the high-yield option-adjusted spread is at 2.93%, up from 2.68% a week ago. That is real widening off historic tights, not a credit accident building. The tightening in play is duration pain, not default pain.